{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007713","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.716539+00:00","generated_at":"2026-05-30T03:31:50.831570+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio reports Phase 1b data: complete & partial responses in cutaneous SCC patients","bullets":["Intratumoral PH-762 well tolerated with no related adverse events or dose-limiting toxicities across 5 patients.","Cohort 2: 1 complete response (100% tumor clearance) and 1 partial response (90% tumor clearance) in cutaneous squamous cell carcinoma.","Phase 1b trial ongoing; enrollment anticipated to complete in Q3 2025.","Data presented at SITC 2024 annual meeting in Houston, TX."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007713","json":"https://secwatch.observer/filing/0001683168-24-007713.json","markdown":"https://secwatch.observer/filing/0001683168-24-007713.md","text":"https://secwatch.observer/filing/0001683168-24-007713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824007713/0001683168-24-007713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824007713/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:31:50.831570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}